Nelson Vergel's Blog, page 13
September 24, 2011
September 15, 2011
Do You Need Testosterone?
Great article published in Charles Poliquin's web site. Charles is one of the world's experts on exercise and powerlifting.
http://www.charlespoliquin.com/ArticlesMultimedia/Articles/Article/694/Do_You_Need_Testosterone_Replacement_Therapy.aspx?lang=EN
http://www.charlespoliquin.com/ArticlesMultimedia/Articles/Article/694/Do_You_Need_Testosterone_Replacement_Therapy.aspx?lang=EN
August 14, 2011
August 9, 2011
Endogenous Testosterone and Mortality in Men: A Systematic Review and Meta-Analysis
Men with low blood levels of testosterone had higher risk of mortality
From: The Journal of Clinical Endocrinology & Metabolism. August 3, 2011 jc.2011-1137
Clinical Review: Endogenous Testosterone and Mortality in Men: A Systematic Review and Meta-Analysis
Andre B. Araujo,
Julia M. Dixon,
Elizabeth A. Suarez,
M. Hassan Murad,
Lin T. Guey and
Gary A. Wittert
-Author Affiliations
From: The Journal of Clinical Endocrinology & Metabolism. August 3, 2011 jc.2011-1137
Clinical Review: Endogenous Testosterone and Mortality in Men: A Systematic Review and Meta-Analysis
Andre B. Araujo,
Julia M. Dixon,
Elizabeth A. Suarez,
M. Hassan Murad,
Lin T. Guey and
Gary A. Wittert
-Author Affiliations
August 3, 2011
A Compilation of Articles Written by Nelson Vergel
For several articles written by Nelson Vergel on testosterone, please visit:
http://www.mesomorphosis.com/blog/author/nelsonvergel/
and the facebook page
http://www.facebook.com/groups/325872205815/
http://www.mesomorphosis.com/blog/author/nelsonvergel/
and the facebook page
http://www.facebook.com/groups/325872205815/
August 1, 2011
Changes in Prostate Specific Antigen in Hypogonadal Men After 12 Months of Testosterone Replacement Therapy: Support for the Prostate Saturation Theory
Those who start at low baseline testosterone had the largest PSA increases. That makes sense since low levels of testosterone reduce prostate volume and prostatic specific antigen to levels under the expected median for a specific age. PDA levels normalized after the first month on the gel.
J Urol. 2011 Jul 23. [Epub ahead of print]Changes in Prostate Specific Antigen in Hypogonadal Men After 12 Months of Testosterone Replacement Therapy: Support for the Prostate Saturation Theory.Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM.SourceScott Department of Urology, Baylor College of Medicine, Houston, Texas.AbstractPURPOSE:We measured prostate specific antigen after 12 months of testosterone replacement therapy in hypogonadal men.MATERIALS AND METHODS:Data were collected from the TRiUS (Testim® Registry in the United States), an observational registry of hypogonadal men on testosterone replacement therapy (849). Participants were Testim naïve, had no prostate cancer and received 5 to 10 gm Testim 1% (testosterone gel) daily.RESULTS:A total of 451 patients with prostate specific antigen and total testosterone values were divided into group A (197 with total testosterone less than 250 ng/dl) and group B (254 with total testosterone 250 ng/dl or greater). The groups differed significantly in free testosterone and sex hormone-binding globulin, but not in age or prostate specific antigen. In group A but not group B prostate specific antigen correlated significantly with total testosterone (r = 0.20, p = 0.005), free testosterone (r = 0.22, p = 0.03) and sex hormone-binding globulin (r = 0.59, p = 0.002) at baseline. After 12 months of testosterone replacement therapy, increase in total testosterone (mean ± SD) was statistically significant in group A (+326 ± 295 ng/dl, p <0.001; final total testosterone 516 ± 28 ng/dl) and group B (+154 ± 217 ng/dl, p <0.001; final total testosterone 513 ± 20 ng/dl). After 12 months of testosterone replacement therapy, increase in prostate specific antigen was statistically significant in group A (+0.19 ± 0.61 ng/ml, p = 0.02; final prostate specific antigen 1.26 ± 0.96 ng/ml) but not in group B (+0.28 ± 1.18 ng/ml, p = 0.06; final prostate specific antigen 1.55 ± 1.72 ng/ml). The average percent prostate specific antigen increase from baseline was higher in group A (21.9%) than in group B (14.1%). Overall the greatest prostate specific antigen was observed after 1 month of treatment and decreased thereafter.CONCLUSIONS:Patients with baseline total testosterone less than 250 ng/dl were more likely to have an increased prostate specific antigen after testosterone replacement therapy than those with baseline total testosterone 250 ng/dl or greater, supporting the prostate saturation hypothesis. Clinicians should be aware that severely hypogonadal patients may experience increased prostate specific antigen after testosterone replacement therapy.Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
J Urol. 2011 Jul 23. [Epub ahead of print]Changes in Prostate Specific Antigen in Hypogonadal Men After 12 Months of Testosterone Replacement Therapy: Support for the Prostate Saturation Theory.Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM.SourceScott Department of Urology, Baylor College of Medicine, Houston, Texas.AbstractPURPOSE:We measured prostate specific antigen after 12 months of testosterone replacement therapy in hypogonadal men.MATERIALS AND METHODS:Data were collected from the TRiUS (Testim® Registry in the United States), an observational registry of hypogonadal men on testosterone replacement therapy (849). Participants were Testim naïve, had no prostate cancer and received 5 to 10 gm Testim 1% (testosterone gel) daily.RESULTS:A total of 451 patients with prostate specific antigen and total testosterone values were divided into group A (197 with total testosterone less than 250 ng/dl) and group B (254 with total testosterone 250 ng/dl or greater). The groups differed significantly in free testosterone and sex hormone-binding globulin, but not in age or prostate specific antigen. In group A but not group B prostate specific antigen correlated significantly with total testosterone (r = 0.20, p = 0.005), free testosterone (r = 0.22, p = 0.03) and sex hormone-binding globulin (r = 0.59, p = 0.002) at baseline. After 12 months of testosterone replacement therapy, increase in total testosterone (mean ± SD) was statistically significant in group A (+326 ± 295 ng/dl, p <0.001; final total testosterone 516 ± 28 ng/dl) and group B (+154 ± 217 ng/dl, p <0.001; final total testosterone 513 ± 20 ng/dl). After 12 months of testosterone replacement therapy, increase in prostate specific antigen was statistically significant in group A (+0.19 ± 0.61 ng/ml, p = 0.02; final prostate specific antigen 1.26 ± 0.96 ng/ml) but not in group B (+0.28 ± 1.18 ng/ml, p = 0.06; final prostate specific antigen 1.55 ± 1.72 ng/ml). The average percent prostate specific antigen increase from baseline was higher in group A (21.9%) than in group B (14.1%). Overall the greatest prostate specific antigen was observed after 1 month of treatment and decreased thereafter.CONCLUSIONS:Patients with baseline total testosterone less than 250 ng/dl were more likely to have an increased prostate specific antigen after testosterone replacement therapy than those with baseline total testosterone 250 ng/dl or greater, supporting the prostate saturation hypothesis. Clinicians should be aware that severely hypogonadal patients may experience increased prostate specific antigen after testosterone replacement therapy.Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
June 25, 2011
The Effect of Antihypertensive Drugs on Erectile Function: A Proposed Management Algorithm - By Michael Doumas MD, Stella Douma
Blood pressure medications are one of the main culprits of erectile dysfunction in men who are aging. This is a great review of medications and algorithm . Too bad that it does not include the use of testosterone in that algorithm!
CLICK HERE
CLICK HERE
June 7, 2011
Testosterone improves memory in women
Too bad most doctors do not check testosterone blood levels in women, and if they do...they do not know how to supplement it. Right now, there is no FDA approved option for women. Libigel will be approved soon , though. Doctors can prescribe gels from compounding pharmacies. The best for women in http://www.womensinternational.com/
http://www.endocrinetoday.com/view.aspx?rid=84459
http://www.endocrinetoday.com/view.aspx?rid=84459
June 3, 2011
How should doctors monitor men receiving testosterone replacement therapy?
Very good short paper that summarizes what several guidelines say about following up men on testosterone replacement. I suggest you print it out and give your doctor a copy since it is simple and short. The summary table is great!
http://stg.jfponline.com/pdf/5912/5912JFP_ClinInq3.pdf
stg.jfponline.com
May 25, 2011
Low testosterone predicts increased mortality and testosterone replacement therapy improves survival in men with type 2 diabetes
Endocrine Abstracts (2011) 25 P163
Low testosterone predicts increased mortality and testosterone replacement therapy improves survival in men with type 2 diabetes
Vakkat Muraleedharan1,2, Hazel Marsh1 & Hugh Jones1,21Barnsley Hospital NHS Foundation Trust, Barnley, UK; 2University of Sheffield, Sheffield, UK.
Background: Low testosterone in men is associated with increase in all-cause and cardiovascular mortality. There is a high prevalence of hypogonadism in men with type 2 diabetes and testosterone replacement therapy (TRT) improves cardiovascular risk. However there is no published data regarding mortality in these patients in relation to testosterone levels, and the long term effect of TRT on mortality.
Aim: We report a 6 year follow-up study examining the effect of baseline testosterone and TRT in hypogonadal men with type 2 diabetes on all-cause mortality.
Methods: Five hundred eighty-seven patients with type 2 diabetes had total testosterone (TT) performed between 2002 and 2005 and were followed up for 5.8±1.3 years.
Deaths during the first 6 months were excluded. Patients were then analysed in three groups. i) normal TT (>10.4 nmol/l) ii) low TT (≤10.4 nmol/l) without TRT. iii) low TT receiving TRT for 2 years or more.Results: Of 580 patients analysed, 338 had normal TT (58%) and 240 low TT (42%). In the low TT group 58 patients received TRT. Mean age 61±11 S.D. and similarly matched in all three groups. Total deaths 72 (12.4%). Mortality rates – low TT without treatment (36/182-20%), normal TT (31/338-9%) and low TT with TRT (5/58-8.6%). Survival was significantly decreased in patients with low TT without TRT (P=0.001 log rank) compared to normal. The treated group had improved survival (P=0.049 log rank). In the Cox Regression model multi-variate (age, weight, HbA1c, pre existing cardiovascular disease, smoking, statin and ACEi/ARB use) adjusted hazard ratio for all-cause mortality was 2.2 (95% CI 1.3–3.7 P=0.001) for low TT.
Conclusions: This study shows that men with type 2 diabetes and low testosterone have a significant increased mortality. TRT improved survival compared to those untreated, recording a similar mortality rate to the normal TT group.Endocrine Abstracts (2011) 25 P163
Low testosterone predicts increased mortality and testosterone replacement therapy improves survival in men with type 2 diabetes
Vakkat Muraleedharan1,2, Hazel Marsh1 & Hugh Jones1,21Barnsley Hospital NHS Foundation Trust, Barnley, UK; 2University of Sheffield, Sheffield, UK.
Background: Low testosterone in men is associated with increase in all-cause and cardiovascular mortality. There is a high prevalence of hypogonadism in men with type 2 diabetes and testosterone replacement therapy (TRT) improves cardiovascular risk. However there is no published data regarding mortality in these patients in relation to testosterone levels, and the long term effect of TRT on mortality.
Aim: We report a 6 year follow-up study examining the effect of baseline testosterone and TRT in hypogonadal men with type 2 diabetes on all-cause mortality.
Methods: Five hundred eighty-seven patients with type 2 diabetes had total testosterone (TT) performed between 2002 and 2005 and were followed up for 5.8±1.3 years.
Deaths during the first 6 months were excluded. Patients were then analysed in three groups. i) normal TT (>10.4 nmol/l) ii) low TT (≤10.4 nmol/l) without TRT. iii) low TT receiving TRT for 2 years or more.Results: Of 580 patients analysed, 338 had normal TT (58%) and 240 low TT (42%). In the low TT group 58 patients received TRT. Mean age 61±11 S.D. and similarly matched in all three groups. Total deaths 72 (12.4%). Mortality rates – low TT without treatment (36/182-20%), normal TT (31/338-9%) and low TT with TRT (5/58-8.6%). Survival was significantly decreased in patients with low TT without TRT (P=0.001 log rank) compared to normal. The treated group had improved survival (P=0.049 log rank). In the Cox Regression model multi-variate (age, weight, HbA1c, pre existing cardiovascular disease, smoking, statin and ACEi/ARB use) adjusted hazard ratio for all-cause mortality was 2.2 (95% CI 1.3–3.7 P=0.001) for low TT.
Conclusions: This study shows that men with type 2 diabetes and low testosterone have a significant increased mortality. TRT improved survival compared to those untreated, recording a similar mortality rate to the normal TT group.Endocrine Abstracts (2011) 25 P163
